Aptevo Therapeutics (APVO) Projected to Post Quarterly Earnings on Tuesday

Aptevo Therapeutics (NASDAQ:APVO) is expected to announce its results after the market closes on Tuesday, May 12th. Analysts expect the company to announce earnings of ($5.60) per share for the quarter.

Aptevo Therapeutics (NASDAQ:APVO) last announced its quarterly earnings results on Thursday, March 26th. The biotechnology company reported $118.23 earnings per share for the quarter, beating analysts’ consensus estimates of ($8.10) by $126.33. On average, analysts expect Aptevo Therapeutics to post $-21 EPS for the current fiscal year and $-19 EPS for the next fiscal year.

Aptevo Therapeutics Price Performance

Shares of NASDAQ:APVO opened at $4.97 on Friday. The business’s fifty day moving average price is $5.07 and its two-hundred day moving average price is $12.38. Aptevo Therapeutics has a fifty-two week low of $3.80 and a fifty-two week high of $258.01. The stock has a market capitalization of $5.86 million, a price-to-earnings ratio of 0.00 and a beta of 1.64.

Hedge Funds Weigh In On Aptevo Therapeutics

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Virtu Financial LLC purchased a new stake in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 38,282 shares of the biotechnology company’s stock, valued at approximately $56,000. Virtu Financial LLC owned 1.16% of Aptevo Therapeutics as of its most recent SEC filing. Institutional investors own 8.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on APVO shares. Wall Street Zen upgraded Aptevo Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, March 29th. Weiss Ratings cut Aptevo Therapeutics from a “sell (e+)” rating to a “sell (e)” rating in a research report on Friday, April 24th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold”.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.